Sep 11, 05
|
| NEW STORY |
| 12:00 ET |
Vicuron Pharmaceuticals - Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Expected Closing Date for Acquisition by Pfizer
|
|
Aug 18, 05
|
| 16:30 ET |
Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/Candidemia
|
|
Aug 15, 05
|
| 16:30 ET |
Vicuron Pharmaceuticals Stockholders Approve Merger With Pfizer
|
|
Aug 04, 05
|
| 16:30 ET |
Vicuron Pharmaceuticals Announces Second Quarter 2005 Financial Results
|
|
Jun 16, 05
|
| 01:00 ET |
Pfizer to Acquire Vicuron Pharmaceuticals to Extend its Research Commitment in Anti-Infectives
|
|
Jun 02, 05
|
| 02:00 ET |
Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark Office
|
|
May 31, 05
|
| 02:00 ET |
Vicuron Pharmaceuticals Files Amendment to Anidulafungin New Drug Application (NDA) for Treatment of Esophageal Candidiasis
|
|
May 26, 05
|
| 16:30 ET |
Vicuron Pharmaceuticals to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference and the Pacific Growth Equities Annual Life Sciences Growth Conference
|
|
May 17, 05
|
| 16:30 ET |
Vicuron Pharmaceuticals to Present at the 2005 Needham Biotech Conference
|
|
May 11, 05
|
| 02:00 ET |
Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug Application
|
|
May 09, 05
|
| 16:30 ET |
Vicuron Pharmaceuticals to Present at the Bear Stearns 2005 Healthcare Conference and the Banc of America Securities Healthcare Conference
|
|
May 05, 05
|
| 16:30 ET |
Vicuron Pharmaceuticals Announces First Quarter 2005 Financial Results
|
|
Apr 28, 05
|
| 07:31 ET |
Vicuron Pharmaceuticals to Present at Morgan Stanley Healthcare Unplugged Conference
|
|
Mar 30, 05
|
| 16:30 ET |
Vicuron Pharmaceuticals Extends Pfizer Deal to Develop Oral Antibiotics for Community Market
|
|